<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03026751</url>
  </required_header>
  <id_info>
    <org_study_id>CCR4384</org_study_id>
    <nct_id>NCT03026751</nct_id>
  </id_info>
  <brief_title>Improving Diagnosis in Idiopathic Cytopenia Using Gene Sequencing</brief_title>
  <official_title>Improving Diagnosis in Idiopathic Cytopenia Using Gene Sequencing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      10% of the cases referred to the specialist diagnostic haemato-pathology service at RMH are&#xD;
      for cytopenias.&#xD;
&#xD;
      The hypothesis to be tested is that a proportion of patients with idiopathic cytopenias have&#xD;
      mutations in myelodysplasic syndrome (MDS)-associated genes. The investigators will sequence&#xD;
      a panel of known MDS-associated genes in patient material (bone marrow and blood) that is&#xD;
      sent routinely to the diagnostic service where conventional techniques have failed to&#xD;
      establish a clear diagnosis. 200 patients with idiopathic cytopenia will be followed up to&#xD;
      determine their survival, blood counts and development of acute leukaemia and other&#xD;
      haematological malignancies. The clinical outcomes will be correlated with any mutations&#xD;
      detected.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with cytopenias will be identified by their local District General Consultant&#xD;
      haematologist and consent obtained. A bone marrow sample will be sent to RMH as per usual&#xD;
      diagnostic pathway.&#xD;
&#xD;
      Once received at the RMH, an aliquot will be frozen down for sequencing by the Molecular&#xD;
      Pathology lab. Only those cases of cytopenia without a specific diagnosis will be the focus&#xD;
      of this study.&#xD;
&#xD;
      Results will be fed back to referring consultants with caveats regarding significance.&#xD;
&#xD;
      Patients will undergo telephone follow up and data will also be provided by local&#xD;
      consultants.&#xD;
&#xD;
      The investigators will look at overall survival, development of haematological malignancies&#xD;
      and full blood count. This will occur annually.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 5, 2017</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with idiopathic cytopenia with a mutation</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">285</enrollment>
  <condition>Cytopenia</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Marrow Aspirate</intervention_name>
    <description>Bone marrow aspirate</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Next-generation sequencing will occur looking at target genes in the marrow to identify&#xD;
      mutations.&#xD;
&#xD;
      DNA will be sequenced to allow us to determine acquired mutations in haematopoietic tissue.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Blood and bone marrow samples are routinely sent to RMH from District General Hospitals for&#xD;
        special tests to make a diagnosis for patients with blood problems.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Patients &gt;= 18 years old&#xD;
&#xD;
          -  Life expectancy more than 12 months&#xD;
&#xD;
          -  Cytopenia defined as Hb &lt; 110g/L and/or Neutrophils &lt;1.5 x109/L and/or Platelets &lt;100&#xD;
             x109/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known haematological malignancy or aplastic anaemia/paroxysmal nocturnal&#xD;
             haemoglobinuria&#xD;
&#xD;
          -  Cytopenia of known aetiology (after examination of blood film and other investigations&#xD;
             have occurred). These include haematinic deficiency (patients unresponsive to&#xD;
             appropriate haematinic deficiency may enter the study), autoimmune cytopenias, chronic&#xD;
             renal anaemia (for those with isolated anaemia), known haemoglobinopathy (for those&#xD;
             with isolated anaemia), chronic viral diseases (Hep B/C/HIV), cytopenias associated&#xD;
             with liver disease, cytopenias associated with systemic autoimmune conditions (eg SLE,&#xD;
             rheumatoid arthritis), anaemia of chronic disease (for those with isolated anaemia).&#xD;
&#xD;
          -  Cytotoxic chemotherapy or other myelosuppressive drugs or radiotherapy within 12&#xD;
             months&#xD;
&#xD;
          -  Inadequate bone marrow sample for gene testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Taussig</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leonora Conneely</last_name>
    <phone>0208 661 3018</phone>
    <email>leonora.conneely@rmh.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorna Smith</last_name>
      <phone>020 8915 6187</phone>
      <email>lorna.smith2@rmh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>David Taussig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>January 18, 2017</study_first_submitted>
  <study_first_submitted_qc>January 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2017</study_first_posted>
  <last_update_submitted>August 25, 2017</last_update_submitted>
  <last_update_submitted_qc>August 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Leukopenia</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

